{
    "clinical_study": {
        "@rank": "164815", 
        "acronym": "CALM-FIM_EUR", 
        "arm_group": {
            "arm_group_label": "MobiusHD", 
            "arm_group_type": "Experimental", 
            "description": "MobiusHD"
        }, 
        "brief_summary": {
            "textblock": "To evaluate the safety and performance of the MobiusHD system in subjects with resistant\n      hypertension."
        }, 
        "brief_title": "Controlling and Lowering Blood Pressure With The MOBIUSHD\u2122 (CALM-FIM_EUR)", 
        "completion_date": {
            "#text": "July 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Hypertension", 
        "condition_browse": {
            "mesh_term": "Hypertension"
        }, 
        "detailed_description": {
            "textblock": "This is an open-label, multicenter, first-in-man clinical trial to be conducted in Europe.\n      Eligible subjects with stage 2 resistant systemic arterial hypertension currently being\n      treate4d with a minimum of three (3) anti-hypertensive drugs, who consent to study\n      participation will be assigned to treatment with the MobiusHD system.\n\n      Potential study participants will be consented and then screened at two (2) baseline visits\n      beginning at least 30 days prior to MobiusHD placement.  Qualified patients will undergo\n      placement of the MobiusHD under angiographic visualization, and will then be followed for 36\n      months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Office cuff SBP \u2265 160 mmHg measured per protocol instructions (Appendix IV) following\n             at least one (1) month of maximally tolerated therapy with at least three (3)\n             anti-hypertensive medications, of which at least one (1) must be a diuretic unless\n             patient has history of intolerance, ineffectiveness or contraindications.  Any\n             combination medications will be counted per the active ingredient (for example,\n             Zestoretic (Lisinopril +HCTZ) equals two (2) anti-hypertensive medications)\n\n        Exclusion Criteria:\n\n          -  Known or clinically suspected baroreflex failure or autonomic neuropathy"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01911897", 
            "org_study_id": "CRD0120"
        }, 
        "intervention": {
            "arm_group_label": "MobiusHD", 
            "description": "Implant that is placed in the carotid sinus to control hypertension.", 
            "intervention_name": "MobiusHD", 
            "intervention_type": "Device"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Hypertension", 
        "lastchanged_date": "September 19, 2013", 
        "location": [
            {
                "contact": {
                    "email": "nele.peeters@zol.be", 
                    "last_name": "Nele Peeters", 
                    "phone": "0032 (0)89327193"
                }, 
                "facility": {
                    "address": {
                        "city": "Genk", 
                        "country": "Belgium", 
                        "zip": "3600"
                    }, 
                    "name": "Ziekenhuis Oost-Limburg"
                }, 
                "investigator": {
                    "last_name": "Jo Dens, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "i.rost@antoniusziekenhuis.nl", 
                    "last_name": "Ilona Rost", 
                    "phone": "+31 (0)30 609 22 78"
                }, 
                "facility": {
                    "address": {
                        "city": "Nieuwegein", 
                        "country": "Netherlands", 
                        "zip": "3430 EM"
                    }, 
                    "name": "St. Antonius Ziekenhuis"
                }, 
                "investigator": {
                    "last_name": "Jan Van der Heyden, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "B.vanCoenen@hagaziekenhuis.nl", 
                    "last_name": "Bart V. Coenen", 
                    "phone": "(+31) 613274143"
                }, 
                "facility": {
                    "address": {
                        "city": "The Hague", 
                        "country": "Netherlands", 
                        "zip": "2545 CH"
                    }, 
                    "name": "HagaZiekenhuis"
                }, 
                "investigator": {
                    "last_name": "Lukas van Dijk, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Belgium", 
                "Netherlands"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "CALM-FIM_EUR - Controlling and Lowering Blood Pressure With the MobiusHD - A Prospective Multicenter Safety Study", 
        "overall_contact": {
            "email": "sshetty@vasculardynamics.com", 
            "last_name": "Sujith J Shetty, MBBS", 
            "phone": "01-650-963-9370"
        }, 
        "overall_official": {
            "affiliation": "St. Antonius Ziekenhuis", 
            "last_name": "Jan Van der Heyden, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Incidence of serious adverse events (SAEs) and unanticipated adverse device effects (UADE) reported for the study population from implantation through six(6) months of follow-up", 
            "measure": "Safety", 
            "safety_issue": "Yes", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01911897"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Decrease in office cuff blood pressure (BP).", 
            "measure": "Performance", 
            "safety_issue": "No", 
            "time_frame": "6 Months"
        }, 
        "source": "Vascular Dynamics, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Vascular Dynamics, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}